Israel's new drug EXO-CD24: 90% of patients with COVID-19 discharged from hospital within 5 days! Fight the cytokine storm!
The new drug is a new drug developed by a team at Sourasky Medical Center in Tel Aviv. "The main goal of this research is to verify whether the drug is safe," said Professor Nadir Arber. "Until today, we have not found any significant side effects in the two groups of patients."

Picture from Al-Ittihad screen
The trial was conducted in Athens because (at the time) there were not enough relevant patients in Israel. The lead researcher is Professor Sotiris Tsiodras, a Greek coronavirus expert. Arber and his team, including Dr. Shiran Shapira, developed the drug based on a molecule called CD24 that the professor has studied for 25 years, which is naturally present in the body.
Clinically, the main reason for the deterioration of the patient's condition is the excessive activation of the immune system, also known as cytokine storm. The drug is aimed at cytokine storm. CD24 is a protein fixed on the cell membrane. It has many functions, including the mechanism of regulating cytokine storms.
Arber emphasized that EXO-CD24 will not affect the entire immune system, but only for this specific mechanism to help find its correct balance again. "We are using the body's endogenous mechanisms to balance the cytokine storm part."
Arber pointed out that another breakthrough of this treatment is its delivery. "We are using exosomes, which are very small vesicles that originate from the cell membrane and are responsible for the exchange of information between them," he said. "By trying to transport them exactly where they are needed, we have avoided many side effects."
Read rose ether in one article
2026-08-08
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Global Chemical Giants Light the Fuse: A TDI/MDI Price Storm Sweeps Asia and Europe—Who’s Fueling This “Cost Carnival”?
-
EU Clears Carlyle's Acquisition of BASF's Coatings Business, but Demands Divestment of Nouryon's Polysulfide Assets: What Are the Underlying Risks?
-
G20 Pushes Fertilizer Access as Food-Security Risk Rises
-
India Prepares New Seed and Pesticide Laws
-
ANVISA Updates Additive Rules
-
Fertilizer Prices Put U.S. Farmers Under Pressure
-
West Asia Tensions Squeeze Pharma Raw Materials
-
Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.
-
U.S. Health Chief Says No Evidence Linking Tylenol to Autism
-
NCP Coatings Acquires Glyptal, Manufacturer of High-Performance Insulating Enamels
Recommend Reading
-
Strides Pharma Reports Strong Q2 as Net Profit Surges 82%
-
EU Authorises Propionic Acid and Its Salts as Feed Additives Until 2035
-
India Strengthens Drug Approval Oversight with Expanded CDSCO Powers
-
EFSA Reports Avian Influenza Situation in Europe and Human Cases in Asia
-
India Targets Fake Drug Packaging
-
Magnesium Chloride (MgCl₂): Properties, Uses, and Applications
-
Premium Global Chemical Sourcing Requests (9-13July, 2026)
-
Supply Reduction Leads to Rapid Increase in n-Butanol Market
-
Premium Global Chemical Sourcing Requests (2-3Jun, 2026)
-
Flavin Adenine Dinucleotide (FAD): Functions and Applications